HFE Genetic Testing: Indications, Interpretation, and Management
HFE genetic testing should be performed after obtaining informed consent in three specific scenarios: (1) individuals with biochemical iron overload (transferrin saturation >45-50% and elevated ferritin), (2) adult first-degree relatives of patients with confirmed C282Y homozygous hemochromatosis, and (3) patients with unexplained persistently elevated transferrin saturation. 1
Algorithmic Approach to Testing
Step 1: Initial Biochemical Screening
- Always begin with serum iron parameters first—never start with genetic testing 1
- Measure transferrin saturation and serum ferritin as the primary screening tests
- For European-descent individuals, proceed to genetic testing if:
- Females: Transferrin saturation >45% AND ferritin >200 μg/L
- Males: Transferrin saturation >50% AND ferritin >300 μg/L 1
Critical pitfall: Approximately 50% of patients referred for HFE testing lack biochemical evidence of iron overload, representing inappropriate test utilization 2. This wastes resources and reduces diagnostic yield.
Step 2: Genetic Testing Protocol
- Test for p.C282Y variant in HFE gene as the primary target 1
- Adult first-degree relatives of C282Y homozygotes should be tested regardless of biochemical parameters 1
- Do NOT routinely measure hepcidin (100% consensus against this) 1
Step 3: Genotype-Specific Interpretation and Management
C282Y Homozygotes (C282Y/C282Y)
- This genotype accounts for >90% of clinically significant hereditary hemochromatosis 3, 4
- These patients require treatment with phlebotomy to prevent end-organ damage including cirrhosis, cardiac disease, and diabetes 3
- Serum ferritin <1,000 ng/mL at diagnosis indicates low risk of advanced hepatic fibrosis and eliminates need for liver biopsy 3
C282Y/H63D Compound Heterozygotes
- Management must be guided by phenotypic presentation and additional risk factors, NOT genotype alone (100% consensus) 1
- If confirmed iron overload exists (by MRI or liver biopsy), investigate for other causes of iron overload 1
- Phlebotomy may be appropriate but requires individualized clinical assessment 1
H63D Homozygotes or H63D Heterozygotes
- Genotyping for p.H63D is NOT generally suggested to guide treatment 1
- The value of testing for this variant remains controversial
- If iron overload is present, search for alternative causes (nonalcoholic fatty liver disease and alcoholic liver disease are more common than HH in these patients) 3
- Management follows phenotype, not genotype 1
Key Management Principles
When Genetic Testing is Positive (C282Y/C282Y)
- Initiate therapeutic phlebotomy before clinical symptoms develop to achieve normal life expectancy 5
- Use MRI to quantify hepatic iron concentration if ferritin is unclear or to assess extrahepatic organ involvement 1
- Perform cardiac MRI if signs of heart disease exist 1
- Counsel patients to avoid raw or undercooked seafood due to >50% mortality risk from Vibrio vulnificus infections in iron-overloaded patients 1
- Strongly discourage heavy alcohol intake 1
When Genetic Testing is Negative but Iron Overload Persists
- Patients with biochemical iron overload who are NOT C282Y homozygotes should be evaluated for secondary causes 3
- Consider nonalcoholic fatty liver disease, alcoholic liver disease, or rare non-HFE hemochromatosis (types 2-4) 3, 6
- Testing for non-HFE genes (HJV, HAMP, TFR2, SLC40A1) is expensive and generally not useful in most clinical settings 3
Evidence Quality and Consensus
The 2022 EASL guidelines represent the highest quality evidence with 100% expert consensus on all major recommendations 1. These supersede older guidelines and demonstrate remarkable agreement on testing criteria. The implementation of these criteria has been shown to improve diagnostic yield dramatically—increasing C282Y homozygote detection from 7.6% to 14.8% while reducing unnecessary testing by 40% 7.
The most important clinical principle: Genetic testing confirms diagnosis but phenotype (biochemical iron parameters, organ involvement, and additional risk factors) determines treatment decisions, particularly for non-C282Y homozygous genotypes.